FIP (Feline Infectious Peritonitis) treatment requires a fast, controlled, and reliable approach, especially in severe and advanced cases. The application form of the product used in this process is critical for the sustainability of treatment.

Safe use when oral intake is not possible in severe cases

In advanced FIP cases:

• Weakening or loss of the swallowing reflex
• Loss of appetite and not eating
• Resistance to oral medication application are frequently observed.

🔹 In such cases, injectable products allow for the continuous maintenance of treatment without the need for oral intake and offer a vital alternative.

Effect independent of the gastrointestinal system

Injectable application bypasses the gastrointestinal system:

• Without being affected by vomiting and regurgitation
• Without loss of absorption
• Provides direct participation in the systemic circulation This feature increases treatment efficacy in severe clinical pictures.

Rapid and predictable bioavailability

Injectable form:

• Ensures rapid entry of the active substance into the circulation
• Contributes to the earlier observation of clinical response
• Minimizes absorption differences This advantage is critical, especially in patients with poor general condition.

Dose control and clinical safety

Injectable products:

• Allow for precise and controlled dose application
• Eliminate the risk of dose loss and irregular intake
• Provide maximum safety under veterinary supervision

Efficacy in critical and initial periods of treatment

Injectable form provides a significant advantage especially:

• In acute and severe stages of the disease
• In cases where oral medication is not possible
• In cases where treatment needs to be started quickly